Approximately 170 physicians or nearly 5% of the total number of prescribers were new Rayaldee prescribers in Q1. We anticipate that sales of Rayaldee will start to rebound as COVID-19 vaccinations become more available and infections decline. To mitigate the impact of the ongoing pandemic, we are continuously training our sales force in virtual selling techniques, boosting our marketing efforts, channels through social media platforms, and redeploying sales personnel to geographies with lower infection rates. We are pleased to announce today that phase 2a results with Rayaldee as a new treatment for SHPT in hemodialysis patients fully confirm the previously reported interim data, cohort 1 of this phase 2 clinical trial, exploring the safety and efficacy of a high-strength formulation of Rayaldee in adults with SHPT, vitamin D insufficiency and stage 5 CKD, who require regular hemodialysis was completed in February 2021.